A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Solid TumorSEQ Core Panel : 1017064
Test CodeMDFCPSTCP or 1017064
CPT Codes
81459
Transport Container
Submit Paraffin embedded tissue (PET) block accompanied by a circled H & E slide indicating the area to be examined: submit in sterile biohazard plastic bag.
Slides: submit 10 x 10 µm PET slides (minimum 5 x 5 µm) and H & E slide in slide holder.
Specimen to be tested must contain a minimum of 10 percent tumor (20 percent preferred).
Slides: submit 10 x 10 µm PET slides (minimum 5 x 5 µm) and H & E slide in slide holder.
Specimen to be tested must contain a minimum of 10 percent tumor (20 percent preferred).
Transport Temperature
Paraffin embedded Tissue Block: Ambient or on ice pack in summer; Slides: Ambient.
Specimen Stability
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Next Generation Sequencing
Setup Schedule
Monday & Wednesday & Friday
Report Available
10-14 days
Reference Range
An interpretive report will be provided.
Clinical Significance
The Solid TumorSEQ Core Panel provides information on 49 genes from a patient’s tumor specimen that may be helpful in guiding cancer treatment. The genes were selected based on actionability of mutations identified in those genes, using currently available evidence from national and international guidelines and literature. This test uses next-generation sequencing to detect mutations present in DNA and RNA extracted from formalin-fixed, paraffin embedded (FFPE) tissue sections of solid tumors. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also evaluated.
The genes tested include: AKT1, AKT2, ALK, AR, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, HRAS, IDH1, JAK2, KIT, KRAS, MAP2K1, MDM2, MET, MTOR, MYC, MYCN, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PTCH1, PTEN, RET, ROS1, TERT, TMPRSS2, TP53, TSC1, and VHL.
The genes tested for translocations include: ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, RET, ROS1, and TMPRSS2.
The genes tested include: AKT1, AKT2, ALK, AR, BAP1, BRAF, BRCA1, BRCA2, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, HRAS, IDH1, JAK2, KIT, KRAS, MAP2K1, MDM2, MET, MTOR, MYC, MYCN, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PTCH1, PTEN, RET, ROS1, TERT, TMPRSS2, TP53, TSC1, and VHL.
The genes tested for translocations include: ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, RET, ROS1, and TMPRSS2.
Performing Laboratory
med fusion